Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Recommendations for Hep C Virus testing of persons born during 1945–1965

This month's Annals of Internal Medicine reports on recommendations from the Centers for Disease Control and prevention Hepatitis C virus testing of persons born during 1945–1965.

News image

The Centers for Disease Control and Prevention developed these evidence-based recommendations to increase the proportion of hepatitis C virus (HCV)–infected persons who know their status and are linked to appropriate care and treatment.

They recommend that adults born during 1945–1965 receive 1-time testing for HCV without prior ascertainment of HCV risk.

The team report that all persons identified with HCV infection receive a brief alcohol screening and intervention as clinically indicated, followed by referral to appropriate care and treatment services for HCV infection and related conditions as indicated.

The Centers for Disease Control and Prevention (CDC) estimates that 3.4 to 4.9 million persons have ever been infected with hepatitis C virus (HCV) in the United States.

All of these persons develop HCV antibodies, and approximately 75% develop a chronic infection.

This results in an estimated 2.7 to 3.9 million persons living with HCV infection in the United States.

Incidence of HCV increased markedly during the 1970s and 1980s, reaching an average of 230,000 new infections each year throughout the 1980s.

Incidence declined rapidly in the 1990s because of effective screening of blood donors starting in 1992, and reduced numbers of new infections among persons who inject drugs.

The CDC reports that the incidence declined until 2006 and has since remained stable, with an estimated 17,000 new infections in 2010.

Those who were infected in the remote past have been living with HCV infection for 20 to 40 years and are at increased risk for HCV-related morbidity and mortality.

Hepatitis C virus infection is the leading indication for liver transplantation, and accounts for more than 50% of incident hepatocellular carcinoma.

The team reports that the fastest-growing cause of cancer-related death in the United States.

The team noted that annual HCV-associated mortality in the United States increased over 50% from 1999 to 2007.

Data from death certificates show that HCV-associated deaths are now more frequent than deaths caused by HIV.

Modeling studies forecast substantial increases in morbidity and mortality among HCV-infected persons as they enter into their third, fourth, and fifth decades of living with infection.

The CDC estimates that without diagnosis and treatment 1.76 million persons with HCV infection will develop cirrhosis during their lifetimes, over 400,000 will develop HCC, and over 1 million will die from HCV-associated disease.

In 1998, the CDC issued recommendations for identifying HCV-infected persons.

Testing for HCV was recommended for persons most likely to be infected, including those who had ever injected drugs, received clotting factor concentrates produced before 1987, ever received long-term hemodialysis, had laboratory evidence of liver disease, or received transfusions of blood or blood components or organ transplants before 1992.

Screening also was recommended for persons who had a recognized blood exposure.

In 1999, HCV testing was recommended for persons infected with HIV.

The success of risk-based testing strategies has been limited.

Depending on the level of risk in the population and site-specific testing practices, an estimated 45% to 85% of U.S. adults are chronically infected with HCV yet unaware of their condition.

Testing for HCV seromarkers is suboptimal even among high-risk populations for whom routine testing is recommended.

The CDC notes that a sizeable percentage of these persons remain unaware of their infection status.

Dr Smith and colleagues conclude, "Because of the limited effectiveness of the current HCV testing recommendations alone in identifying undiagnosed infections, the CDC considered a birth year–based HCV testing strategy to increase the proportion of infected persons who know their HCV infection status."

"1-time HCV testing of persons born during 1945–1965."

"These persons account for 76.5% of all prevalence of those with HCV antibodies."

"Because alcohol accelerates progression of liver disease in HCV-infected persons, the CDC also addressed brief alcohol screening for those with HCV infection."

Ann Intern Med 2012; 157(11): 817-822
07 December 2012

Go to top of page Email this page Email this page to a colleague

 19 April 2015

Advanced search
 17 April 2015 
MELD score and colorectal resection
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
CRP and acute diverticulitis
 13 April 2015 
Immune based treatments for HCC
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Nonceliac gluten sensitivity
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 07 April 2015 
Endoscopic managements of GI bleeds
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Treatment of Hep C virus
 06 April 2015 
Treatment for rectal cancer
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Treatment of pediatric IBD
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 25 March 2015 
Cytomegalovirus and IBD
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us